专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100129358A1 METHOD OF DETECTING OCULAR DISEASES AND PATHOLOGIC CONDITIONS AND TREATMENT OF SAME 审中-公开
标题翻译：检测卵巢疾病和病理状况及其治疗方法
公开(公告)号：US20100129358A1
公开(公告)日：2010-05-27
申请号：US12520055
申请日：2007-12-21
申请人： Kang Zhang , Zenglin Yang , Haoyu Chen , Dean Li
发明人： Kang Zhang , Zenglin Yang , Haoyu Chen , Dean Li
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/76 , C07K2317/92 , C12N9/6424 , C12Q1/6883 , C12Q1/6888 , C12Q2600/156 , C12Q2600/158 , C12Y304/21 , G01N33/573 , G01N2800/16
摘要： Ocular diseases affecting the macula or the vasculature of the eye affect a wide variety of individuals. In particular, Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world and has a significant genetic predisposition. Methods of analyzing one or more mutations in the HtrA1 gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye are provided. The methods of the present invention may further include analysis of the CFH gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye. Compositions and methods for treating ocular disease and pathologic conditions of the eye are also provided.
摘要翻译：影响黄斑或眼睛脉管系统的眼部疾病影响各种各样的个体。特别是年龄相关性黄斑变性（AMD）是发达国家不可逆视觉丧失的最常见原因，具有重要的遗传倾向。提供了分析HtrA1基因中的一个或多个突变以便鉴定具有对眼部疾病发展的可预测性和眼睛的病理状况并诊断目前患有眼部疾病或眼睛病理状况的患者的方法。本发明的方法还可以包括对CFH基因的分析，以便鉴定具有对眼部疾病的发展和眼睛病理状况的前瞻性的个体，并诊断目前患有眼部疾病或目前患有眼部疾病眼。还提供了用于治疗眼部疾病和眼睛病理状况的组合物和方法。

2. 发明申请

US20100166743A1 METHOD OF DETECTING OCULAR DISEASES AND PATHOLOGIC CONDITIONS AND TREATMENT OF SAME 审中-公开
标题翻译：检测卵巢疾病和病理状况及其治疗方法
公开(公告)号：US20100166743A1
公开(公告)日：2010-07-01
申请号：US12444558
申请日：2007-10-08
申请人： Kang Zhang , Zenglin Yeng , Haoyu Chen , Dean Li
发明人： Kang Zhang , Zenglin Yeng , Haoyu Chen , Dean Li
IPC分类号： A61K39/395 , C07K16/18 , A61P27/02
CPC分类号： C07K16/40 , A61K2039/505 , C07K2317/31 , C07K2317/76 , C07K2317/92 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/573 , G01N2333/96433 , G01N2800/16
摘要： Methods of detecting and treating diseases and pathological conditions of the eye are disclosed. In particular a genetic variant of the HtrA1 gene is correlated to age related macular degeneration (AMD). In addition, biologically active agents capable of inhibiting HtrA1 activity are provided, and methods of treating diseases and pathological conditions of the eye are additionally disclosed.
摘要翻译：公开了检测和治疗眼睛疾病和病理状况的方法。特别地，HtrA1基因的遗传变体与年龄相关的黄斑变性（AMD）相关。此外，提供能够抑制HtrA1活性的生物活性剂，另外公开了治疗眼睛疾病和病理状况的方法。

3. 发明授权

US08530043B2 Composite laminate composition 有权
标题翻译：复合层压组合物
公开(公告)号：US08530043B2
公开(公告)日：2013-09-10
申请号：US13000037
申请日：2009-06-25
申请人： Dean Li , Dongbiao Wang
发明人： Dean Li , Dongbiao Wang
IPC分类号： B32B7/02 , B32B27/36
CPC分类号： B32B27/08 , B32B7/12 , B32B27/302 , B32B27/304 , B32B27/308 , B32B27/36 , B32B27/365 , B32B27/40 , B32B37/12 , B32B2250/02 , B32B2250/03 , B32B2250/04 , B32B2250/24 , B32B2270/00 , B32B2307/3065 , B32B2369/00 , B32B2479/00 , B32B2607/00 , B32B2607/02 , Y10T428/24967 , Y10T428/31507
摘要： A multi-layer composite laminate composition having a substrate layer and an overlay layer that are both bonded to at least one adjacent layer in a multi-layer composite laminate composition; the substrate layer being a thermoformable material having a material formulation that includes a polycarbonate homopolymer or copolymer; the overlay layer being a thermoformable material having a material formulation that includes an ingrediant selected from the group consisting of PVC, PVC alloy, acrylic, polyurethane, acrylonitrile butadiene styrene, and combinations thereof.
摘要翻译：一种多层复合层叠组合物，其具有在多层复合层叠组合物中与至少一个相邻层结合的基底层和覆盖层; 所述基材层是具有包含聚碳酸酯均聚物或共聚物的材料配方的可热成型材料; 所述覆盖层是可热成型材料，其具有包含选自由PVC，PVC合金，丙烯酸，聚氨酯，丙烯腈丁二烯苯乙烯及其组合组成的组的材料配方。

4. 发明授权

US08309519B2 Compositions and methods for inhibiting vascular permeability 有权
标题翻译：抑制血管通透性的组合物和方法
公开(公告)号：US08309519B2
公开(公告)日：2012-11-13
申请号：US13111776
申请日：2011-05-19
申请人： Dean Li , Christopher Jones , Nyall London
发明人： Dean Li , Christopher Jones , Nyall London
IPC分类号： A61K38/16 , A61K38/17 , C07K14/435
CPC分类号： A61K38/17 , A61K38/00 , C07K14/70503 , G01N33/5023 , G01N2800/164
摘要： Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.
摘要翻译：本文描述了用于抑制血管通透性和病理性血管生成的化合物，组合物和方法。本文还描述了生产和筛选能够抑制血管通透性和病理性血管生成的化合物和组合物的方法。药物组合物包括在本文所述的组合物中。本文描述的组合物可用于例如抑制血管通透性和病理性血管生成的方法，包括抑制由特异性血管生成，通透性和炎性因子（例如VEGF，bFGF和凝血酶）诱导的血管通透性和病理性血管发生的方法。本文还提供了治疗特定疾病和病症的方法。

5. 发明申请

US20110223400A1 COMPOSITE LAMINATE COMPOSITION 有权
标题翻译：复合层压板组合物
公开(公告)号：US20110223400A1
公开(公告)日：2011-09-15
申请号：US13000037
申请日：2009-06-25
申请人： Dean Li , Dongbiao Wang
发明人： Dean Li , Dongbiao Wang
IPC分类号： B32B27/08 , B32B7/02
CPC分类号： B32B27/08 , B32B7/12 , B32B27/302 , B32B27/304 , B32B27/308 , B32B27/36 , B32B27/365 , B32B27/40 , B32B37/12 , B32B2250/02 , B32B2250/03 , B32B2250/04 , B32B2250/24 , B32B2270/00 , B32B2307/3065 , B32B2369/00 , B32B2479/00 , B32B2607/00 , B32B2607/02 , Y10T428/24967 , Y10T428/31507
摘要： A multi-layer composite laminate composition having a substrate layer and an overlay layer that are both bonded to at least one adjacent layer in a multi-layer composite laminate composition; the substrate layer being a thermoformable material having a material formulation that includes a polycarbonate homopolymer or copolymer; the overlay layer being a thermoformable material having a material formulation that includes an ingrediant selected from the group consisting of PVC, PVC alloy, acrylic, polyurethane, acrylonitrile butadiene styrene, and combinations thereof.
摘要翻译：一种多层复合层叠组合物，其具有在多层复合层叠组合物中与至少一个相邻层结合的基底层和覆盖层; 所述基材层是具有包含聚碳酸酯均聚物或共聚物的材料配方的可热成型材料; 所述覆盖层是可热成型材料，其具有包含选自由PVC，PVC合金，丙烯酸，聚氨酯，丙烯腈丁二烯苯乙烯及其组合组成的组的材料配方。

6. 发明申请

US20100069301A1 COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIC ANGIOGENESIS AND VASCULAR PERMEABILITY 有权
标题翻译：治疗病态血管生成和血管渗透性的组合物和方法
公开(公告)号：US20100069301A1
公开(公告)日：2010-03-18
申请号：US12518730
申请日：2007-12-11
申请人： Dean Li , Christopher Jones , Nyall London
发明人： Dean Li , Christopher Jones , Nyall London
IPC分类号： A61K38/16 , C07K7/08 , C07K7/06 , C07K14/00 , A61K38/08 , A61K38/10 , A61P35/00
CPC分类号： A61K38/17 , A61K38/00 , C07K14/70503 , G01N33/5023 , G01N2800/164
摘要： Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.
摘要翻译：本文描述了用于抑制血管通透性和病理性血管生成的化合物，组合物和方法。本文还描述了生产和筛选能够抑制血管通透性和病理性血管生成的化合物和组合物的方法。药物组合物包括在本文所述的组合物中。本文描述的组合物可用于例如抑制血管通透性和病理性血管生成的方法，包括抑制由特异性血管生成，通透性和炎性因子（例如VEGF，bFGF和凝血酶）诱导的血管通透性和病理性血管发生的方法。本文还提供了治疗特定疾病和病症的方法。

7. 发明授权

US06291356B1 Method for etching silicon oxynitride and dielectric antireflection coatings 失效
标题翻译：蚀刻氮氧化硅和介电抗反射涂层的方法
公开(公告)号：US06291356B1
公开(公告)日：2001-09-18
申请号：US09317655
申请日：1999-05-24
申请人： Pavel Ionov , Sung Ho Kim , Dean Li , Chun Yan , James Chang Wang
发明人： Pavel Ionov , Sung Ho Kim , Dean Li , Chun Yan , James Chang Wang
IPC分类号： H01L21302
CPC分类号： H01L21/32139 , H01L21/0276 , H01L21/31116 , H01L21/3143
摘要： The present disclosure pertains to a method for plasma etching a semiconductor film stack. The film stack includes at least one layer comprising silicon oxynitride. The method includes etching the silicon oxynitride-comprising layer using an etchant gas mixture comprising chlorine and at least one compound containing fluorine and carbon. The atomic ratio of fluorine to chlorine in the etchant gas ranges between about 3:1 and about 0.01:1; preferably, between about 0.5:1 and about 0.01:1; most preferably, between about 0.25:1 and about 0.1:1. The etchant gas forms a fluorine-comprising polymer or species which deposits on exposed surfaces adjacent to the silicon oxynitride-comprising layer in an amount sufficient to reduce the etch rate of an adjacent material (such as a photoresist) while permitting the etching of the silicon oxynitride-comprising layer.
摘要翻译：本公开涉及用于等离子体蚀刻半导体膜堆叠的方法。薄膜叠层包括至少一层包含氮氧化硅的层。该方法包括使用包含氯和至少一种含氟和碳的化合物的蚀刻剂气体混合物来蚀刻含氧氮化硅层。蚀刻剂气体中氟与氯的原子比范围为约3:1至约0.01:1; 优选约0.5:1至约0.01:1; 最优选在约0.25:1至约0.1:1之间。蚀刻剂气体形成含氟聚合物或物质，它们以足以降低邻近材料（例如光致抗蚀剂）蚀刻速率的量沉积在与含氮氧化硅层相邻的暴露表面上，同时允许蚀刻硅含氧氮化物的层。

8. 发明申请

US20060019896A1 Netrin-related compositions and uses 有权
标题翻译： Netrin相关成分和用途
公开(公告)号：US20060019896A1
公开(公告)日：2006-01-26
申请号：US11183136
申请日：2005-07-14
申请人： Dean Li , Kye Park
发明人： Dean Li , Kye Park
IPC分类号： A61K38/17 , A61K38/18
CPC分类号： A61K38/18 , A61K38/179 , A61K38/1825 , A61K38/1858 , A61K38/1866 , A61K38/1891 , A61K2300/00
摘要： The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types.
摘要翻译：本发明提供用于调节心血管细胞类型的增殖，分化，迁移和粘附的方法和组合物。

9. 发明申请

US20050223419A1 Mice which are +/- or -/- for the elastin gene as models for vascular disease 有权
标题翻译：作为血管疾病模型的弹性蛋白基因的+/-或 - / - 小鼠
公开(公告)号：US20050223419A1
公开(公告)日：2005-10-06
申请号：US11046006
申请日：2005-01-28
申请人： Mark Keating , Dean Li
发明人： Mark Keating , Dean Li
IPC分类号： A61K38/39 , A61L31/04 , A61P9/10 , A01K67/027 , A61K38/54 , C12N5/06
CPC分类号： A61L31/047 , A61K38/39 , A61L31/043
摘要： Elastin, the main component of arterial extracellular matrix, was thought to have a purely structural role. Consistent with this view, elastin hemizygous mice maintain arterial extensibility by increasing the number of elastic lamellae during development. However, mice lacking elastin die of obstructive arterial pathology. This pathology results from subendothelial proliferation and reorganization of smooth muscle, cellular changes similar to those observed in atherosclerosis. Thus, elastin is a molecular determinant of arterial morphogenesis and likely plays a central role in vascular disease. Mice which are heterozygous and null for the elastin gene have been developed. These mice are extremely useful for screening for drugs useful for treating persons with atherosclerosis, hypertension, SVAS or other vascular diseases.
摘要翻译：动弹性细胞外基质的主要成分弹性蛋白被认为具有纯粹的结构作用。与此观点一致，弹性蛋白半合子小鼠通过在发育过程中增加弹性薄片的数量来维持动脉的伸展性。然而，缺乏阻塞性动脉病理学弹性蛋白酶的小鼠。这种病理学结果来自内皮细胞增殖和平滑肌重组，细胞变化与动脉粥样硬化中观察到的细胞变化相似。因此，弹性蛋白是动脉形态发生的分子决定因素，并且可能在血管疾病中起核心作用。已经开发了对于弹性蛋白基因是杂合的和无效的小鼠。这些小鼠对于筛选可用于治疗动脉粥样硬化，高血压，SVAS或其他血管疾病的药物非常有用。

10. 发明授权

US06537918B2 Method for etching silicon oxynitride and dielectric antireflection coatings 失效
标题翻译：蚀刻氮氧化硅和介电抗反射涂层的方法
公开(公告)号：US06537918B2
公开(公告)日：2003-03-25
申请号：US09920251
申请日：2001-07-31
申请人： Pavel Ionov , Sung Ho Kim , Dean Li , Chun Yan , James Chang Wang
发明人： Pavel Ionov , Sung Ho Kim , Dean Li , Chun Yan , James Chang Wang
IPC分类号： H01L21302
CPC分类号： H01L21/32139 , H01L21/0276 , H01L21/31116 , H01L21/3143
摘要： A method for plasma etching a semiconductor film stack. The film stack includes at least one layer comprising silicon oxynitride. The method includes etching the silicon oxynitride-comprising layer using an etchant gas mixture comprising chlorine and at least one compound containing fluorine and carbon. The atomic ratio of fluorine to chlorine in the etchant gas ranges between about 3:1 and about 0.01:1; preferably, between about 0.5:1 and about 0.01:1; most preferably, between about 0.25:1 and about 0.1:1. The etchant gas forms a fluorine-comprising polymer or species which deposits on exposed surfaces adjacent to the silicon oxynitride-comprising layer in an amount sufficient to reduce the etch rate of an adjacent material (such as a photoresist) while permitting the etching of the silicon oxynitride-comprising layer.
摘要翻译：一种用于等离子体蚀刻半导体膜堆叠的方法。薄膜叠层包括至少一层包含氮氧化硅的层。该方法包括使用包含氯和至少一种含氟和碳的化合物的蚀刻剂气体混合物来蚀刻含氧氮化硅层。蚀刻剂气体中氟与氯的原子比范围为约3:1至约0.01:1; 优选约0.5:1至约0.01:1; 最优选在约0.25:1至约0.1:1之间。蚀刻剂气体形成含氟聚合物或物质，它们以足以降低邻近材料（例如光致抗蚀剂）蚀刻速率的量沉积在与含氮氧化硅层相邻的暴露表面上，同时允许蚀刻硅含氧氮化物的层。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式